Evidence of reliability and validity of the opiate dosage adequacy scale (ODAS) in a sample of methadone maintenance patients

Heroin Addiction and Related Clinical Problems

Volumn 10, Issue 1, 2008, Pages 25-38

  González Saiz, Francisco ^a   Rojas, Oscar Lozano ^a   Gómez, Rosario Ballesta ^a   Acedos, Izaskun Bilbao ^a   Martínez, Javier Galiana ^b   Collantes, Ma Angeles García ^b   Fernández, Antonio López ^b  

^a Fundacion Andaluza para la Atencion a Las Drogodependencias e Incorporacion Social   (Spain)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

Author keywords

Assessment; Methadone; Opiate dosage adequacy scale; Opiates; Plasma level

Indexed keywords

DIAMORPHINE; DRUG METABOLITE; METHADONE; OROSOMUCOID;

ADDICTION SEVERITY INDEX; ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONSTRUCT VALIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; FATIGUE; FEMALE; HEROIN DEPENDENCE; HUMAN; INSOMNIA; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MULTICENTER STUDY; NAUSEA; OPIATE ADDICTION; OPIATE DOSAGE ADEQUACY SCALE; OUTCOMES CLINICAL IMPRESSION FORM; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEMI STRUCTURED INTERVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; URINALYSIS;

EID: 41649116223     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. BALL J.C., ROSS C.A. (1991): The Effectiveness of Methadone Maintenance Treatment. Springer-Verlag, New York.
2. BELL J., SERES V., BOWRON P., LEWIS J., BATEY R. (1988): The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol. Ther. 43: 623-629.
3. BIRKETT D.J. (2002): Therapeutic drug monitoring. In: Birkett D.J.; Pharmacokinetics made easy. Revised. Roseville, MacGraw-Hill.
4. CAPLEHORN J.R., BELL J. (1991): Methadone dosage and retention of patients in maintenance treatment. The Medical Journal of Australia. 154: 195-199.
5. CAPLEHORN J.R. (1993): A comparison of abstinence-oriented and indefinite methadone maintenance treatment. The International Journal of Addictions 29(11): 1361-1375.
6. CAPLEHORN J.R., BELL J., KLEINBAUM D.G., GEBSKI V.J. (1993): Methadone dose and heroin use during maintenance treatment. Addiction 88: 119-124.
7. CAPLEHORN J.R., MCNEILL D.R., KLEINBAUM D.G. (1993): Clinic policy and retention in methadone maintenance. The International Journal of the Addictions 28(1): 73-89.
8. CAPLEHORN J.R., IRWIG L., SAUNDERS J.B. (1996): Attitudes and beliefs of staff working in methadone clinics. Substance Use & Misuse 31(4): 437-452.
9. CAPLEHORN J.R., IRWIG L., SAUNDERS J.B. (1996): Physicians' attitudes and retention of patients in their methadone maintenance program. Substance Use & Misuse 31(6): 663-677.
10. CAPONE C.T., LOPEZ HAGGERTY E.L., ACER K., MELCHIONDA R., HOLLEY E., ADAMS H., LOGAN F. (1994): Client variables associated with selection and outcome in a methadone tapering program. The International Journal of the Addictions. 29(3): 387-394.
11. CICCHETII DV (1994:) Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol. Assess. 6(4): 284-290.
12. COHEN J (1960): A coefficient of agreement for nominal scales. Educational and Psychological Meassurement, 20: 37-46.
13. CONDELLI W.S. (1993): Strategies for increasing retention in methadone programs. J. Psychoactive Drugs. 25(2): 143-147.
14. CRONBACH LJ (1951): Coefficient alpha and the internal structure of test. Psychometrika 16: 297-334.
15. CONDELLI W.S., DUNTEMAN G.H. (1993): Exposure to methadone programs and heroin use. Am. J. Drug Alcohol Abuse. 19(1): 65-78.
16. DE VOS J.W., UFKES J.G.R., VAN BRUSSEL G.H.A., VAN DEN BRINK W. (1996): Craving despite extremely high methadone dose. Drug Alcohol Depend. 40: 181-184.
17. DARKE S, HALL W, WODAK A, HEATHER N, WARD J (1992): Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. British Journal of Addiction 87: 733-742.
18. DARKE S. (1998): The effectiveness of methadone treatment 3: moderators of treatment outcome. In: Ward J., Mattick R.P. & Hall W. (Ed.) Methadone maintenance treatment and other opioid replacement therapies. Amsterdam, Harwood Academic Publishers.
19. DENNIS ML, PERL HI, HUEBNER RB, MCLELLAN AT (2000): Twenty-five strategies for improving the design, implementation and analysis of health services research to alcohol and other drug abuse treatment. Addiction 95: S281-S308.
20. DOLE V.P., NYSWANDER M.E. (1966): Narcotic blockade. Arch Intern Med. 118: 304-309.
21. DYER K.R., WHITE J.M. (1997): Patterns of symptom complaints in methadone maintenance patients. Addiction. 92 (11): 1445-1455.
22. EAP C.B., DÉGLON J-J, BAUMMAN P. (1999): Pharmacokinetics and pharmacogenetics of methadone: clinical relevance. Heroin Addict Relat Clin Probl. 1(1): 19-34.
23. GOSSOP M (2004): Multiple substance use and multiple dependences. In: Kranzler HR, Tinsley JA (Ed.) Dual diagnosis and psychiatric treatment. Substance abuse and comorbid disorders. Second edition, New York, Marcel Dekker. Pp. 129-156.
24. HALL W., WARD J., MATTICK R.P. (1998): The effectiveness of methadone treatment 1: heroin use and crime. In: Ward J., Mattick R.P. & Hall W. (Ed.) Methadone maintenance treatment and other opioid replacement therapies , Amsterdam, Harwood Academic Publishers.
25. HILTUNEN A.J., LAFOLIE P., MARTEL J., OTTOSSON E.C., BOREUS L.O., BECK O., HJEMGAHL P. (1995): Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychoapharmacology (Berl). 118: 122-126.
26. HUBBARD R.L. (1997): Evaluation and outcome of treatment. In: Lowinson J.H., Ruiz P., Millman R.B., Langrod J.G. (Ed.) Substance Abuse: A Comprehensive Textbook, Third edition. (Baltimore, Williams & Wilkins).
27. GONZÁLEZ-SAIZ F. (1997): Estandarización de un instrumento de evaluación multidimensional en los trastornos adictivos. Tesis Doctoral. Universidad de Cádiz.
28. GONZÁLEZ-SAIZ F. (2004): Opiate Dosage Adequacy Scale (O.D.A.S.): a clinical diagnostic tool as a guide to dosing decisions. Heroin Addict Relat Clin Probl. 6(3): 41-50.
29. JOFRE-BONET M., SINDELAR J.L. (2004): Creating an aggregate outcome index: cost-effectiveness analysis of substance abuse treatment. Journal of Behavioural Health Services & Research 31(3): 229-241.
30. JOHNSON E.E., CHRISTIE M.J., CONNOR M. (2005): The role of opioid receptor phosphorilation and trafficking in adaptations to persistent opioid treatment. Neurosignals 14(6): 290-302.
31. KAISER HG (1970): A second generation little jiffy, Psychometrika, 35: 401.
32. KAYMAN D.J., GOLDSTEIN M.F., DEREN S., ROSENBLUM A. (2006): Predicting treatment with a brief "Opinions About Methadone" scale. J Psychoactive Drugs. 38(1): 93-100.
33. KELL M.J. (1994): Utilization of plasma and urine methadone concentrations to optimise treatment in maintenance clinics I: Measurement techniques for a clinical setting. J Addict Dis 13(1): 5-26.
34. KELL M.J. (1995): Utilization of plasma and urine methadone concentrations measurements to limit narcotics use in methadone maintenance patients II: Generations of plasma concentration response curves. J Addict Dis 14(1): 85-108.
35. KREEK M.J., BART G., LILLY C., LAFORGE K.S., NIELSEN D.A. (2005): Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57(1): 1-26.
36. LEAVITT S.B.; SHINDERMAN M., MAXWELL S., EAP C.B., PARIS P. (2000): When "enough" is not enough: New perspectives on optimal methadone maintenance dose. The Mount Sinai Journal of Medicine 67(5): 404-411.
37. LEAVITT S.B. (2003): Methadone dosing & safety in the treatment of opioid addiction. Addiction Treatment Forum 12(2): 1-8.
38. LÓPEZ ML, BAÑO MD, GUILLÉN JL (2001): Algoritmo e interpretación de los niveles plasmáticos de metadona. Trastornos Adictivos 3(4): 244-255.
39. LOIMER N., SCHMID R. (1992): The use of plasma levels to optimise methadone maintenance treatment. Drug and Alcohol Dependence 30: 241-246.
40. LOTSCH J., SKARKE C., WIETING J., OERTEL B.G., SCHMIDT H., BROCKMOLLER J., GEISSLINGER G. (2006): Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.Clin Pharmacol Ther. 79(1): 72-89.
41. LUBRANO S., PACINI M., GIUNTOLI G., MAREMMANI I. (2002): Is craving for heroin and alcohol related to low methadone dosages in methadone maintenance patients?. Heroin Add Relat Clin Probl. 4(2): 11-18.
42. MADDUX JF, PRIHODA TJ, VOGTSBERGER KN (1997): The relationship of methadone dose and other variables to outcomes of methadone maintenance. Am. J. Addict. (6): 246-255.
43. MAREMMANI I., PACINI M., LUBRANO S., LOVRECIC M. (2003): When "enough" is still not "enough". Effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Addict Relat Clin Probl. 5(1): 17-32.
44. MAZUMDAR M, GLASSMAN JR (2000): Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Statistics in Medicine 19(1): 113-132.
45. MCLELLAN A.T., ARNDT I.O., METZGER D.S., WOODY G.E., O'BRIEN C.P. (1993): The effects of psychosocial services in substance abuse treatment. J. Am. Med. Assoc. 296: 1953-1959.
46. MCLELLAN A.T., KUSHNER H., METZGER D., PETERS R., SMITH I., GRISSOM G., PETTINATI H., ARGERIOU M (1992): The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9; 199-213.
47. NUNNALLY, J.C. (1978): Psychometric Theory, New York, McGraw-Hill.
48. NWAKEZE, P.C., MAGURA S., DEMSKY S. (1997): Patient and program effects on retention in methadone treatment: A preliminary report. Journal of Maintenance in the Addiction 1(1): 63-74.
49. OKRUHLICA L., DEVINSK F., VALENTOVA J, KLEMPOVA D. (2002): Does therapeutic threshold of methadone concentration in plasma exist?. Heroin Addict Relat Clin Probl. 4(1): 29-36.
50. PAYTE J.T., KHURI E.T. (1993): Principles of methadone dose determination. In: Parrino M. (Ed.) State Methadone Treatment Guidelines. U.S. Department of Health & Human Services, Rockville, MD. Pp. 47-58.
51. PAYTE J.T., ZWEBEN J.E., MARTIN J. (2003): Opioid maintenance treatment. In: Graham A.W., Schultz T.K., Mayo-Smith M.F., Ries R.K., Wilford B.B. (Ed.) Principles of Addiction Medicine, Third Edition Maryland, Chevy Chase.
52. PAYTE J.T. (2004): Bad patients or bad treatment?. Heroin Addict Relat Clin Probl. 6(3): 37-40.
53. PÉREZ DE LOS COBOS J.C., TRUJOLS J., VALDERRAMA J.C., VALERO S., PUIG T. (2005): Patient perspective on methadone maintenance treatment in the Valencia Region: Dose adjustment, participation in dosage regulation, and satisfaction with treatment. Drug Alcohol Depend 79(3): 405-412.
54. SHROUT PE, FLEISS JL (1979) Reliability. In: Tsuang MT, Tohen M, Zahner GEP Eds.) Textbook in Psychiatric Epidemiology, New York, John Wiley & Sons.
55. SPITZER RL, ENDICOTT J, ROBINS E (1975): Clinical criteria for psychiatric diagnosis and DSM-III. Am J Psychiatry 132: 1187-1192.
56. STEVENS J (1992): Applied multivariate statistics for the social sciences, Hillsdale, NJ, Lawrence Erlbaum.
57. STRAIN E.C., STITZER M.L., LIEBSON I.A., BIGELOW G.E. (1993a): Dose-effects of methadone in the treatment of opioid dependence. Ann Internal Med. 119: 23-27.
58. STRAIN E.C., STITZER M.L., LIEBSON I.A., BIGELOW G.E. (1993B): Methadone dose and treatment outcome. Drug Alcohol Depend. 33: 105-117.
59. STRAIN E.C., STITZER M.L., LIEBSON I.A., BIGELOW G.E. (1996): Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and Addiction Severity Index. Journal of Clinical Psychoapharmacology 16(1): 58-67. [da controllare anche qui quella prima lettera 'a'!!!]
60. STRAIN E.C., STITZER M.L., LIEBSON I.A., BIGELOW G.E. (1998): Useful predictors of outcome in methadone-treatment patients: Results from a controlled clinical trial with three dose of methadone. Journal of Maintenance in the Addictions 1(3): 15-28.
61. TORRENS M., CASTILLO C., SAN L., DEL MORAL E., GONZÁLEZ M.L., DE LA TORRE R. (1998): Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in methadone maintenance program. Drug Alcohol Depend. 52(3): 193-200.
62. TRAFTON J.A., MINKEL J., HUMPHREYS K. (2006): Determining effective methadone doses for individual opioid-dependent patients. PLoS Med 3(3): e80.
63. YU L. (1996): The m opioid receptor: from molecular cloning to functional studies. Addiction Biology. 1: 19-30.
64. WARD J., MATTICK R.P., HALL W. (1998): The effectiveness of methadone treatment 2: HIV and infectious hepatitis. In: Ward J., Mattick R.P. & Hall W. (Ed.) Methadone maintenance treatment and other opioid replacement therapies Amsterdam, Harwood Academic Publishers.
65. WARD J., MATTICK R.P., HALL W. (1998): The use of methadone during maintenance treatment: pharmacology, dosage and treatment outcome. In: Ward J., Mattick R.P. & Hall W. (Ed.) Methadone maintenance treatment and other opioid replacement therapies Amsterdam, Harwood Academic Publishers.
66. WILLENBRING ML, HAGEDORN HJ, POSTIER AC, KENNY M (2004): Variations in evidence-based clinical practices in nine United States Veterans Administration opioid agonist therapy clinics. Drug Alcohol Depend 75: 97-106.
67. WOLFF K., KAY A.W.M., RAISTRICK D. (1992): Plasma methadone measurements and their role in methadone detoxification programs. Clin Chem. 38: 420-425.
68. WOLFF K., ROSTAMI-HODJEGAN A., HAY A.W.M., RAISTRICK D., TUCKER G. (2000): Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction. 95(12): 1771-1783.